江苏浩欧博生物医药股份有限公司 股东会议事规则 第一章 总 则 第一条 为规范江苏浩欧博生物医药股份有限公司（以下简称"公司"）行 为，保证股东会依法行使职权，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）《上市公 司治理准则》《上市公司股东会规则》等法律法规、规范性文件及《江苏浩欧博 生物医药股份有限公司章程》（以下简称"《公司章程》"）的规定，制定本议 事规则。 第二条 公司应当严格按照法律、行政法规、本议事规则及《公司章程》的 相关规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会是公司的权力机构，依法行使下列职权： （六） 对公司合并、分立、解散、清算或者变更公司形式作出决议； （七） 修改《公司章程》； （八） 对公司聘用、解聘承办公司审计业务的会计师事务所作出决议； （九） 审议批准《公司章程》第四十七条规定的对外担保及交易行为； （十） 审议公司在一年内购买、出售重大资产超过公司最近一期经审计总 资产 30%的事项 ...

江苏浩欧博生物医药股份有限公司 关联交易制度 第一章 总则 第一条 为保证江苏浩欧博生物医药股份有限公司（以下简称"公司"） 与关联人之间的关联交易符合公平、公正、公开的原则，确保公司的关联交易行 为不损害公司和非关联股东的合法权益，根据《中华人民共和国公司法》《中华 人民共和国证券法》《上海证券交易所科创板股票上市规则》（以下简称"《上 市规则》"）、《企业会计准则第 36 号——关联方披露》等有关法律法规、规 范性文件及《江苏浩欧博生物医药股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，制定本制度。 第二条 公司与关联人之间的关联交易行为除遵守有关法律法规、规范性 文件和《公司章程》的规定外，还需遵守本制度的规定。 第二章 关联人和关联关系 第三条 公司关联人包括关联法人（或者其他组织）和关联自然人。 第四条 具有以下情形之一的法人（或者其他组织），为公司的关联法人 （或者其他组织）： （一）直接或间接控制公司的法人（或者其他组织）； （二）由前项所述法人（或者其他组织）直接或间接控制的除公司、控股子 公司及控制的其他主体以外的法人（或者其他组织）； （三）由本制度第五条所列公司的关联自然人直 ...

江苏浩欧博生物医药股份有限公司 对外担保制度 第五条 公司对外担保应当遵循合法、审慎、互利、安全的原则，严格控制担 保风险。 第二章 对外担保的审批权限 第六条 公司做出任何对外担保，须经公司董事会或经股东会批准后方可办 理。 第七条 对于董事会权限范围内的担保事项，除应当经全体董事的过半数通过 1 第一章 总则 第一条 为规范江苏浩欧博生物医药股份有限公司（以下简称"公司"）的对 外担保行为，防范财务风险，保证公司资产安全，根据《中华人民共和国公司法》 《中华人民共和国证券法》《上海证券交易所科创板股票上市规则》（以下简称"《上 市规则》"）等法律法规、规范性文件及《江苏浩欧博生物医药股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，特制定《江苏浩欧博生物医药股份有 限公司对外担保制度》（以下简称"本制度"）。 第二条 本制度所称对外担保，是指公司为他人提供的担保，包括公司对控股 子公司的担保。公司及公司控股子公司的对外担保总额，是指包括公司对控股子公 司在内的公司对外担保总额与公司控股子公司对外担保总额之和。担保形式包括保 证、抵押、质押或其他担保方式。 第三条 公司全体董事及高级管理人员应审慎 ...

Core Viewpoint - The company reported a decline in revenue for the third quarter, while net profit showed significant growth compared to the previous year [1] Group 1: Financial Performance - The company's revenue for the third quarter was 103 million yuan, representing a year-on-year decrease of 1.64% [1] - The net profit for the third quarter was 14.02 million yuan, showing a year-on-year increase of 113.01% [1] - For the first three quarters, the company's revenue totaled 292 million yuan, down 4.84% year-on-year [1] - The net profit for the first three quarters was 26.19 million yuan, reflecting a slight decline of 1.41% year-on-year [1]

Group 1 - The core point of the news is that Jiangsu Haobio Pharmaceutical Co., Ltd. experienced a decline in stock price, dropping by 5.11% to 148.07 CNY per share, with a total market capitalization of 9.399 billion CNY as of the report date [1] - The company, established on June 8, 2009, and listed on January 13, 2021, specializes in the research, production, and sales of in vitro diagnostic reagents, with 89.46% of its revenue coming from reagent sales [1] - The company's revenue composition includes 5.86% from other sales, 3.84% from instrument sales, and 0.85% from rental sales [1] Group 2 - From the perspective of fund holdings, only one fund, Shenwan Hongyuan Fund's Medical Pioneer Stock A, has a significant position in Haobio, holding 56,100 shares, which accounts for 5.74% of the fund's net value [2] - The fund has reported a loss of approximately 447,500 CNY today, with a year-to-date loss of 7% and a one-year loss of 10.41% [2] - The fund manager, Yao Hongfu, has been in charge for 3 years and 98 days, with the fund's total asset size at 133 million CNY, and the best and worst returns during his tenure being -31.23% and -32.27%, respectively [2]

Group 1 - The core point of the news is that Jiangsu Haobo Bio-Pharmaceutical Co., Ltd. has seen a stock price increase of 5.1%, reaching 169.21 yuan per share, with a total market capitalization of 10.741 billion yuan [1] - The company, established on June 8, 2009, specializes in the research, production, and sales of in vitro diagnostic reagents, with reagent sales accounting for 89.46% of its main business revenue [1] - Other revenue sources include sales from other products at 5.86%, instrument sales at 3.84%, and rental sales at 0.85% [1] Group 2 - From the perspective of major fund holdings, one fund under Nuoan Fund has heavily invested in Haobo, with Nuoan Jingxin Mixed Fund holding 17,100 shares, representing 5.9% of the fund's net value [2] - The fund has achieved a year-to-date return of 51% and a one-year return of 57.74%, ranking 453 out of 8,026 in its category [2] - The fund manager, Li Yuliang, has a tenure of over 10 years, with the best fund return during his management being 193.95% [2]

Group 1 - Haobio signed a framework agreement with Roche Diagnostics for the procurement of chemiluminescent antibody detection products, which will enhance brand recognition and market share in China, although the agreement does not specify financial details and may have limited impact on stock price [1] - Chengda Bio entered into a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious disease prevention, which is expected to synergize with existing vaccine development platforms [2] - Shengxiang Bio plans to invest 20 million yuan in a fund aimed at innovative healthcare startups, aligning with its strategic development and investment direction [3] Group 2 - China National Pharmaceutical Group reported a revenue of approximately 39.38 billion yuan and a net profit of about 1.49 billion yuan for the first three quarters of 2025, reflecting a slight increase in both metrics despite industry competition [4] - Puluo Pharmaceutical announced a revenue of approximately 7.76 billion yuan and a net profit of about 700 million yuan for the first three quarters of 2025, indicating a decline in performance due to pressures in the formulation and raw material drug sectors, with expectations for gradual recovery next year [5]

Core Viewpoint - The signing of the cooperation framework agreement between Haobor and Roche Diagnostics is a significant step in implementing the company's long-term development strategy, aimed at enhancing brand recognition and expanding market share in the diagnostic reagent field [1]. Group 1: Partnership Details - Haobor has entered into a cooperation framework agreement with Roche Diagnostics (Shanghai) Co., Ltd. to collaborate in the field of chemiluminescent self-antibody testing products [1]. - This partnership is expected to facilitate mutual learning and communication, allowing both companies to improve their capabilities and provide higher quality products and services to customers [1]. Group 2: Strategic Implications - The collaboration is seen as beneficial for increasing Haobor's brand recognition in the domestic market [1]. - The agreement is anticipated to positively impact Haobor's development by further expanding its market share in the diagnostic reagent sector [1].

Core Viewpoint - The signing of the framework agreement between the company and Roche Diagnostics is a significant step in implementing the company's long-term development strategy, focusing on the field of chemiluminescent self-antibody testing products [1] Group 1: Partnership Details - The framework agreement was signed on October 21, 2025, in Suzhou, and serves as a foundational and guiding document for mutual cooperation projects between the company and Roche Diagnostics [1] - The agreement does not involve specific financial amounts, indicating a focus on collaboration rather than immediate financial commitments [1] Group 2: Strategic Implications - The collaboration is expected to enhance the company's brand recognition in the domestic market, which is crucial for expanding its market share in the diagnostic reagent sector [1] - The partnership will facilitate communication and learning between the two entities, allowing the company to continuously improve its capabilities and provide higher quality products and services to customers [1]

Core Viewpoint - The signing of the cooperation framework agreement between Haobor (688656.SH) and Roche Diagnostics (Shanghai) Co., Ltd. is a significant step in implementing the company's long-term development strategy, aimed at enhancing brand recognition and expanding market share in the diagnostic reagent field [1] Group 1: Cooperation Agreement - The cooperation framework agreement focuses on the field of chemiluminescent self-antibody testing products [1] - The collaboration is expected to facilitate mutual learning and improve the quality of products and services offered to customers [1] - The agreement serves as a non-binding framework statement, meaning it does not impose legal obligations or grounds for liability for breach of contract [1] Group 2: Market Impact - The partnership is anticipated to positively impact the company's development by increasing its market presence in the domestic market [1] - The specific projects under this cooperation will require separate agreements, indicating potential uncertainties in the implementation of the collaboration [1]